Dr. Atkins on Results of Atezolizumab Plus Bevacizumab in RCC

Michael B. Atkins, MD
Published: Wednesday, Jun 28, 2017



Michael B. Atkins, MD, deputy director, Georgetown-Lombardi Comprehensive Cancer Center, professor of oncology and medicine, Georgetown University School of Medicine, discusses the results of a trial of atezolizumab (Tecentriq) plus bevacizumab (Avastin) in renal cell carcinoma (RCC).

Results of the combination of atezolizumab plus bevacizumab was active in both the atezolizumab- and sunitinib (Sutent)-refractory populations. Response rates ranged from 24% to 28%.

There was also a prolongation of progression-free survival in the second-line treatment, as compared with frontline treatment, says Atkins.
 


Michael B. Atkins, MD, deputy director, Georgetown-Lombardi Comprehensive Cancer Center, professor of oncology and medicine, Georgetown University School of Medicine, discusses the results of a trial of atezolizumab (Tecentriq) plus bevacizumab (Avastin) in renal cell carcinoma (RCC).

Results of the combination of atezolizumab plus bevacizumab was active in both the atezolizumab- and sunitinib (Sutent)-refractory populations. Response rates ranged from 24% to 28%.

There was also a prolongation of progression-free survival in the second-line treatment, as compared with frontline treatment, says Atkins.
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Cancer Summaries and Commentaries™: Update from Chicago: Advances in the Treatment of Breast CancerJul 31, 20181.0
Community Practice Connections™: The Next Generation in Renal Cell Carcinoma Treatment: An Oncology Nursing Essentials WorkshopJul 31, 20181.5
Publication Bottom Border
Border Publication
x